NCT05805904View on ClinicalTrials.gov

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 29, 2023

Primary Completion Date

May 23, 2023

Study Completion Date

May 23, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986278

Specified dose on specified days.

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

200032

Local Institution - 0001, Shanghai

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05805904 - A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter